-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On the evening of August 14, Kexing Pharmaceuticals (68813SH) announced that the clinical trial application for "human interferon α2b spray" submitted by the company has been accepted by the State Food and Drug Administratio.
On the evening of August 14, Kexing Pharmaceuticals (68813SH) announced that the clinical trial application for "human interferon α2b spray" submitted by the company has been accepted by the State Food and Drug Administratio.
This is the third clinical trial application for antiviral drugs disclosed by Kexing Pharma on a rolling basis for three consecutive month.
Kexing Pharmaceuticals (68813SH) is an innovative international biopharmaceutical enterprise mainly engaged in the research and development, production and sales of recombinant protein drugs and microecological preparation.
It is understood that interferon can be described as a "sword" in the field of anti-viru.
The human interferon α2b spray applied for this time is a class 2 improved new drug independently developed by Kexing Pharmaceutical.
Kexing Pharmaceuticals stated that the advancement of the research and development of the company's human interferon α2b spray will help optimize the company's product structure, enrich the product pipeline, enhance the company's overall research and development capabilities, and enhance the company's long-term profitabilit.
Another product application for clinical application! Kexing Pharmaceutical's long-term product research and development breakthrough